U.S. markets closed
  • S&P 500

    4,566.48
    +21.58 (+0.47%)
     
  • Dow 30

    35,741.15
    +64.13 (+0.18%)
     
  • Nasdaq

    15,226.71
    +136.51 (+0.90%)
     
  • Russell 2000

    2,312.64
    +21.37 (+0.93%)
     
  • Crude Oil

    83.62
    -0.14 (-0.17%)
     
  • Gold

    1,808.90
    +2.10 (+0.12%)
     
  • Silver

    24.62
    +0.03 (+0.13%)
     
  • EUR/USD

    1.1610
    -0.0035 (-0.30%)
     
  • 10-Yr Bond

    1.6350
    -0.0200 (-1.21%)
     
  • GBP/USD

    1.3761
    +0.0001 (+0.01%)
     
  • USD/JPY

    113.7300
    +0.2700 (+0.24%)
     
  • BTC-USD

    62,996.89
    +2,174.95 (+3.58%)
     
  • CMC Crypto 200

    1,502.82
    +1,260.14 (+519.26%)
     
  • FTSE 100

    7,222.82
    +18.27 (+0.25%)
     
  • Nikkei 225

    28,600.41
    -204.44 (-0.71%)
     

Kymera's KT-474 Achieved Sustained IRAK4 Reduction After Single Dose In Healthy Volunteers

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Kymera Therapeutics Inc (NASDAQ: KYMR) has announced interim results from the Single Ascending Dose (SAD) portion of the Phase 1 trial of KT-474 in healthy volunteers.

  • KT-474 has exceeded the Phase 1 target degradation of 85% to date, with robust IRAK4 degradation after a single oral dose lasting for at least six days at all dose levels.

  • No treatment-related adverse events have been observed to date.

  • Also, the FDA has lifted the partial clinical hold on the Multiple Ascending Dose (MAD) portion of the Phase 1 trial of KT-474. Kymera plans to initiate repeat dosing in July 2021.

  • A subsequent cohort in the Phase 1 trial will include up to 20 patients with atopic dermatitis and hidradenitis suppurativa.

  • Kymera expects to present updated results from the healthy volunteer SAD and MAD portions of the trial in Q4 of 2021.

  • Kymera will host a conference call and webcast today at 8:00 a.m. ET.

  • Price Action: KYMR shares are up 8.16% at $48 in the premarket session on the last check Monday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.